Optimizing antimicrobial therapy in critically ill patients

References

• KumarARobertsDWoodKEDuration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shockCrit Care Med20063461589159616625125
   PubMed Web of Science ®Google Scholar
• KumarAEllisPArabiYCooperative Antimicrobial Therapy of Septic Shock Database Research GroupInitiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shockChest200913651237124819696123
   PubMed Web of Science ®Google Scholar
• TrenholmeGMKaplanRLKarakusisPHClinical impact of rapid identification and susceptibility testing of bacterial blood culture isolatesJ Clin Microbiol1989276134213452473995
   PubMed Web of Science ®Google Scholar
• DupuyAMPhilippartFPéanYMaurice Rapin Institute Biomarkers GroupRole of biomarkers in the management of antibiotic therapy: an expert panel review: I – currently available biomarkers for clinical use in acute infectionsAnn Intensive Care2013312223837559
   PubMed Web of Science ®Google Scholar
• QuenotJPLuytCERocheNRole of biomarkers in the management of antibiotic therapy: an expert panel review II: clinical use of biomarkers for initiation or discontinuation of antibiotic therapyAnn Intensive Care2013312123830525
   PubMed Web of Science ®Google Scholar
• EmonetSShahHNCherkaouiASchrenzelJApplication and use of various mass spectrometry methods in clinical microbiologyClin Microbiol Infect201016111604161320969670
   PubMed Web of Science ®Google Scholar
• La ScolaBRaoultDDirect identification of bacteria in positive blood culture bottles by matrix-assisted laser desorption ionisation time-of-flight mass spectrometryPloS One2009411e804119946369
   PubMed Web of Science ®Google Scholar
• NevilleSALecordierAZiochosHUtility of matrix-assisted laser desorption ionization-time of flight mass spectrometry following introduction for routine laboratory bacterial identificationJ Clin Microbiol20114982980298421632894
   PubMed Web of Science ®Google Scholar
• SengPDrancourtMGourietFOngoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometryClin Infect Dis200949454355119583519
   PubMed Web of Science ®Google Scholar
• BlondiauxNGaillotOCourcolR-JMALDI-TOF mass spectrometry to identify clinical bacterial isolates: evaluation in a teaching hospital in LillePathol Biol (Paris)20105815557 French19892496
   PubMedGoogle Scholar
• FerroniASuarezSBerettiJLReal-time identification of bacteria and Candida species in positive blood culture broths by matrix-assisted laser desorption ionization-time of flight mass spectrometryJ Clin Microbiol20104851542154820237092
   PubMed Web of Science ®Google Scholar
• Nyvang HartmeyerGKvistholm JensenABöcherSMass spectrometry: pneumococcal meningitis verified and Brucella species identified in less than half an hourScand J Infect Dis201042971671820429713
   PubMed Web of Science ®Google Scholar
• FerreiraLSánchez-JuanesFGonzález-AvilaMDirect identification of urinary tract pathogens from urine samples by matrix-assisted laser desorption ionization-time of flight mass spectrometryJ Clin Microbiol20104862110211520392910
   PubMed Web of Science ®Google Scholar
• ChangSSHsiehWHLiuTSMultiplex PCR system for rapid detection of pathogens in patients with presumed sepsis - a systemic review and meta-analysisPLoS One201385e6232323734173
   PubMed Web of Science ®Google Scholar
• ManciniNCarlettiSGhidoliNCicheroPBurioniRClementiMThe era of molecular and other non-culture-based methods in diagnosis of sepsisClin Microbiol Rev201023123525120065332
   PubMed Web of Science ®Google Scholar
• ChangSSHsiehWHLiuTSMultiplex PCR system for rapid detection of pathogens in patients with presumed sepsis – a systemic review and meta-analysisPloS One201385e6232323734173
   PubMed Web of Science ®Google Scholar
• DierkesCEhrensteinBSiebigSLindeHJReischlUSalzbergerBClinical impact of a commercially available multiplex PCR system for rapid detection of pathogens in patients with presumed sepsisBMC Infect Dis2009912619671147
   PubMed Web of Science ®Google Scholar
• HirschEBTamVHImpact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomesExpert Rev Pharmacoecon Outcomes Res201010444145120715920
   PubMed Web of Science ®Google Scholar
• ZarrilliRPournarasSGiannouliMTsakrisAGlobal evolution of multidrug-resistant Acinetobacter baumannii clonal lineagesInt J Antimicrob Agents2013411111923127486
   PubMed Web of Science ®Google Scholar
• FalagasMEMarakiSKarageorgopoulosDEKastorisACMavromanolakisESamonisGAntimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycinInt J Antimicrob Agents201035324024320034765
   PubMed Web of Science ®Google Scholar
• KontopidouFGiamarellouHKaterelosPGroup for the Study of KPC-producing Klebsiella pneumoniae infections in intensive care unitsInfections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic optionsClin Microbiol Infect2014202O117O12323992130
   PubMed Web of Science ®Google Scholar
• TamVHHirschEBLascoTMGentryLOPalmerHRCorrelation of hospital carbapenem consumption and resistance trends in selected gram-negative bacteriaAnn Pharmacother2012467–81120112222764323
   PubMed Web of Science ®Google Scholar
• LivermoreDMDefining an extended-spectrum beta-lactamaseClin Microbiol Infect200814Suppl 131018154524
   PubMed Web of Science ®Google Scholar
• LivermoreDMCantonRGniadkowskiMCTX-M: changing the face of ESBLs in EuropeJ Antimicrob Chemother200759216517417158117
   PubMed Web of Science ®Google Scholar
• RossoliniGMD’AndreaMMMugnaioliCThe spread of CTX-M-type extended-spectrum beta-lactamasesClin Microbiol Infect200814Suppl 1334118154526
   PubMed Web of Science ®Google Scholar
• PatersonDLBonomoRAExtended-spectrum β-lactamases: a clinical updateClin Microbiol Rev200518465768616223952
   PubMed Web of Science ®Google Scholar
• BabicMHujerAMBonomoRAWhat’s new in antibiotic resistance? Focus on beta-lactamasesDrug Resist Updat20069314215616899402
   PubMed Web of Science ®Google Scholar
• HansonNDAmpC beta-lactamases: what do we need to know for the future?J Antimicrob Chemother20035212412775673
   PubMed Web of Science ®Google Scholar
• TammaPDGirdwoodSCTGopaulRThe use of cefepime for treating AmpC β-lactamase-producing EnterobacteriaceaeClin Infect Dis201357678178823759352
   PubMed Web of Science ®Google Scholar
• BrinkAJCoetzeeJCorcoranCEmergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tractJ Clin Microbiol201351136937223152549
   PubMed Web of Science ®Google Scholar
• HirschEBChangKTLascoTMCaeiroJPTamVHEmergence of KPC-producing Klebsiella pneumoniae in TexasDiagn Microbiol Infect Dis201169223423521251574
   PubMed Web of Science ®Google Scholar
• CornagliaGAkovaMAmicosanteGESCMID Study Group for Antimicrobial Resistance Surveillance (ESGARS)Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issuesInt J Antimicrob Agents200729438038817223319
   PubMed Web of Science ®Google Scholar
• Walther-RasmussenJHøibyNOXA-type carbapenemasesJ Antimicrob Chemother200657337338316446375
   PubMed Web of Science ®Google Scholar
• QueenanAMBushKCarbapenemases: the versatile beta-lactamasesClin Microbiol Rev200720344045817630334
   PubMed Web of Science ®Google Scholar
• Walther-RasmussenJHøibyNClass A carbapenemasesJ Antimicrob Chemother200760347048217595289
   PubMed Web of Science ®Google Scholar
• PatelGBonomoRA“Stormy waters ahead”: global emergence of carbapenemasesFront Microbiol201344823504089
   PubMed Web of Science ®Google Scholar
• NordmannPPoirelLThe difficult-to-control spread of carbapenemase producers in Enterobacteriaceae worldwideClin Microbiol Infect Epub6142014
   Web of Science ®Google Scholar
• Hidalgo-GrassCWarburgGTemperVKPC-9, a novel carbapenemase from clinical specimens in IsraelAntimicrob Agents Chemother201256116057605922964247
   PubMed Web of Science ®Google Scholar
• PournarasSProtonotariouEVoulgariEClonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in GreeceJ Antimicrob Chemother200964234835219525514
   PubMed Web of Science ®Google Scholar
• TumbarelloMVialePViscoliCPredictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapyClin Infect Dis201255794395022752516
   PubMed Web of Science ®Google Scholar
• FalagasMETansarliGSKarageorgopoulosDEVardakasKZDeaths attributable to carbapenem-resistant Enterobacteriaceae infectionsEmerg Infect Dis20142071170117524959688
   PubMed Web of Science ®Google Scholar
• Papadimitriou-OlivgerisMMarangosMChristofidouMRisk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unitScand J Infect Dis201446964264825017796
   PubMed Web of Science ®Google Scholar
• HoVPJenkinsSGAfanehCITurbendianHKNicolauDPBariePSUse of meropenem by continuous infusion to treat a patient with a Bla(kpc-2)-positive Klebsiella pneumoniae blood stream infectionSurg Infect (Larchmt)201112432532721859337
   PubMed Web of Science ®Google Scholar
• PetrosilloNGiannellaMLewisRVialePTreatment of carbapenem-resistant Klebsiella pneumoniae: the state of the artExpert Rev Anti Infect Ther201311215917723409822
   PubMed Web of Science ®Google Scholar
• Levy HaraGGouldIEndimianiADetection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working GroupJ Chemother201325312914023783137
   PubMed Web of Science ®Google Scholar
• DjahmiNDunyach-RemyCPantelADekhilMSottoALavigneJPEpidemiology of carbapenemase-producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean countriesBioMed Res Int2014201430578424955354
   PubMed Web of Science ®Google Scholar
• StockIInfectious diseases caused by carbapenemase-producing Enterobacteriaceae – a particular challenge for antibacterial therapyMed Monatsschr Pharm2014375162172 German24908928
   PubMedGoogle Scholar
• Munoz-PriceLSPoirelLBonomoRAClinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemasesLancet Infect Dis201313978579623969216
   PubMed Web of Science ®Google Scholar
• PaulMCarmeliYDurante-MangoniECombination therapy for carbapenem-resistant Gram-negative bacteriaJ Antimicrob Chemother20146992305230924872346
   PubMed Web of Science ®Google Scholar
• LandelleCMarimuthuKHarbarthSInfection control measures to decrease the burden of antimicrobial resistance in the critical care settingCurr Opin Crit Care201420549950625032821
   PubMed Web of Science ®Google Scholar
• TurnidgeJDThe pharmacodynamics of beta-lactamsClin Infect Dis199827110229675443
   PubMed Web of Science ®Google Scholar
• CraigWAPharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and menClin Infect Dis19982611109455502
   PubMed Web of Science ®Google Scholar
• McKinnonPSPaladinoJASchentagJJEvaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T.MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsInt J Antimicrob Agents200831434535118313273
   PubMed Web of Science ®Google Scholar
• MoutonJWVinksAAContinuous infusion of beta-lactamsCurr Opin Crit Care200713559860617762242
   PubMed Web of Science ®Google Scholar
• MoutonJWden HollanderJGKilling of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic modelAntimicrob Agents Chemother19943859319368067772
   PubMed Web of Science ®Google Scholar
• RoosendaalRBakker-WoudenbergIAvan den Berghe-van RaffeMVink-van den BergJCMichelMFImpact of the duration of infection on the activity of ceftazidime, gentamicin and ciprofloxacin in Klebsiella pneumoniae pneumonia and septicemia in leukopenic ratsEur J Clin Microbiol Infect Dis19911012101910251839380
   PubMed Web of Science ®Google Scholar
• PeaFVialePFurlanutMAntimicrobial therapy in critically ill patientsClin Pharmacokinet200544101009103416176116
   PubMed Web of Science ®Google Scholar
• RobertsJAJoyntGMChoiGYSGomersallCDLipmanJHow to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamicsInt J Antimicrob Agents201239318719222226651
   PubMed Web of Science ®Google Scholar
• MehrotraRDe GaudioRPalazzoMAntibiotic pharmacokinetic and pharmacodynamic considerations in critical illnessIntensive Care Med200430122145215615536528
   PubMed Web of Science ®Google Scholar
• RobertsJAPeaFLipmanJThe clinical relevance of plasma protein binding changesClin Pharmacokinet20135211823150213
   PubMed Web of Science ®Google Scholar
• UlldemolinsMRelloJThe relevance of drug volume of distribution in antibiotic dosingCurr Pharm Biotechnol201112121996200121554218
   PubMed Web of Science ®Google Scholar
• UdyAARobertsJABootsRJPatersonDLLipmanJAugmented renal clearance: implications for antibacterial dosing in the critically illClin Pharmacokinet201049111620000886
   PubMed Web of Science ®Google Scholar
• UdyAARobertsJAShorrAFBootsRJLipmanJAugmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patientsCrit Care2013171R3523448570
   PubMed Web of Science ®Google Scholar
• UdyAAVargheseJMAltukroniMSubtherapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrationsChest20121421303922194591
   PubMed Web of Science ®Google Scholar
• CarlierMDe WaeleJJIdentifying patients at risk for augmented renal clearance in the ICU – limitations and challengesCrit Care201317213023672959
   PubMed Web of Science ®Google Scholar
• CarlierMCarretteSRobertsJAMeropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?Crit Care2013173R8423642005
   PubMed Web of Science ®Google Scholar
• CasuGSHitesMJacobsFCan changes in renal function predict variations in β-lactam concentrations in septic patients?Int J Antimicrob Agents201342542242823993066
   PubMed Web of Science ®Google Scholar
• MolitorisBAMeasuring glomerular filtration rate in the intensive care unit: no substitutes pleaseCrit Care201317518124004539
   PubMed Web of Science ®Google Scholar
• BaptistaJPUdyAASousaEA comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearanceCrit Care2011153R13921651804
   PubMed Web of Science ®Google Scholar
• EylerRFMuellerBAMedscapeAntibiotic dosing in critically ill patients with acute kidney injuryNat Rev Nephrol20117422623521343897
   PubMed Web of Science ®Google Scholar
• FissellWHAntimicrobial dosing in acute renal replacementAdv Chronic Kidney Dis2013201859323265600
   PubMed Web of Science ®Google Scholar
• JamalJAEconomouCJLipmanJRobertsJAImproving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenationCurr Opin Crit Care201218546047122820155
   PubMed Web of Science ®Google Scholar
• BoumanCSAntimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous veno-venous hemofiltrationCurr Opin Crit Care200814665465919023912
   PubMed Web of Science ®Google Scholar
• TrotmanRLWilliamsonJCShoemakerDMSalzerWLAntibiotic dosing in critically ill adult patients receiving continuous renal replacement therapyClin Infect Dis20054181159116616163635
   PubMed Web of Science ®Google Scholar
• SeylerLCottonFTacconeFSRecommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapyCrit Care2011153R13721649882
   PubMed Web of Science ®Google Scholar
• RobertsJAUlldemolinsMRobertsMSTherapeutic drug monitoring of beta-lactams in critically ill patients: proof of conceptInt J Antimicrob Agents201036433233920685085
   PubMed Web of Science ®Google Scholar
• RobertsDMRobertsJARobertsMSRENAL Replacement Therapy Study InvestigatorsVariability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic studyCrit Care Med20124051523152822511133
   PubMed Web of Science ®Google Scholar
• MüllerMdela PeñaADerendorfHIssues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissueAntimicrob Agents Chemother20044851441145315105091
   PubMed Web of Science ®Google Scholar
• JoukhadarCFrossardMMayerBXImpaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shockCrit Care Med200129238539111246321
   PubMed Web of Science ®Google Scholar
• SauermannRDelle-KarthGMarsikCPharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patientsAntimicrob Agents Chemother200549265065515673747
   PubMed Web of Science ®Google Scholar
• Van HerendaelBJeurissenATulkensPMContinuous infusion of antibiotics in the critically ill: the new holy grail for beta-lactams and vancomycin?Ann Intensive Care2012212222747633
   PubMed Web of Science ®Google Scholar
• Abdul-AzizMHDulhuntyJMBellomoRLipmanJRobertsJAContinuous beta-lactam infusion in critically ill patients: the clinical evidenceAnn Intensive Care2012213722898246
   PubMed Web of Science ®Google Scholar
• DulhuntyJMRobertsJADavisJSContinuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trialClin Infect Dis201356223624423074313
   PubMed Web of Science ®Google Scholar
• FalagasMETansarliGSIkawaKVardakasKZClinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysisClin Infect Dis201356227228223074314
   PubMed Web of Science ®Google Scholar
• Gonçalves-PereiraJPóvoaPAntibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactamsCrit Care2011155R20621914174
   PubMed Web of Science ®Google Scholar
• AubertGCarricajoACoudrotMGuyomarc’hSAuboyerCZeniFProspective determination of serum ceftazidime concentrations in intensive care unitsTher Drug Monit201032451751920571462
   PubMed Web of Science ®Google Scholar
• DellitTHOwensRCMcGowanJEInfectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardshipClin Infect Dis200744215917717173212
   PubMed Web of Science ®Google Scholar
• CarlingPFungTKillionATerrinNBarzaMFavorable impact of a multidisciplinary antibiotic management program conducted during 7 yearsInfect Control Hosp Epidemiol200324969970614510254
   PubMed Web of Science ®Google Scholar
• LaRoccoAJrConcurrent antibiotic review programs – a role for infectious diseases specialists at small community hospitalsClin Infect Dis200337574274312942418
   PubMed Web of Science ®Google Scholar
• RüttimannSKeckBHartmeierCMaetzelABucherHCLong-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospitalClin Infect Dis200438334835614727204
   PubMed Web of Science ®Google Scholar
• NgCKWuTCChanWMClinical and economic impact of an antibiotics stewardship programme in a regional hospital in Hong KongQual Saf Health Care200817538739218842981
   PubMedGoogle Scholar
• SlainDSarwariARPetrosKOImpact of a multimodal antimicrobial stewardship program on Pseudomonas aeruginosa susceptibility and antimicrobial use in the intensive care unit settingCrit Care Res Pract2011201141642621687626
   PubMedGoogle Scholar
• KatsiosCMBurryLNelsonSAn antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patientsCrit Care201216R21623127353
   PubMed Web of Science ®Google Scholar
• GentryCAGreenfieldRASlaterLNWackMHuyckeMMOutcomes of an antimicrobial control program in a teaching hospitalAm J Health Syst Pharm200057326827410674779
   PubMed Web of Science ®Google Scholar
• RahalJJUrbanCHornDClass restriction of cephalosporin use to control total cephalosporin resistance in nosocomial KlebsiellaJAMA199828014123312379786372
   PubMed Web of Science ®Google Scholar
• KimJWChungJChoiSHEarly use of imipenem/cilastatin and vancomycin followed by de-escalation versus conventional antimicrobials without de-escalation for patients with hospital-acquired pneumonia in a medical ICU: a randomized clinical trialCrit Care2012161R2822336530
   PubMed Web of Science ®Google Scholar
• Garnacho-MonteroJGutiérrez-PizarrayaAEscoresca-OrtegaADe-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shockIntensive Care Med2014401324024026297
   PubMed Web of Science ®Google Scholar
• Gomes SilvaBNAndrioloRBAtallahANSalomãoRDe-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock [review]Cochrane Database Syst Rev201012CD00793421154391
   PubMed Web of Science ®Google Scholar
• ShimeNSatakeSFujitaNDe-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patientsInfection201139431932521509424
   PubMed Web of Science ®Google Scholar
• JohnsonJKSmithGLeeMSThe role of patient-to-patient transmission in the acquisition of imipenem-resistant Pseudomonas aeruginosa colonization in the intensive care unitJ Infect Dis2009200690090519673646
   PubMed Web of Science ®Google Scholar
• GeorgePMorrisAMPro/con debate: should antimicrobial stewardship programs be adopted universally in the intensive care unit?Crit Care201014120520236505
   PubMed Web of Science ®Google Scholar
• RimawiRHMazerMASirajDSGoochMCookPPImpact of regular collaboration between infectious diseases and critical care practitioners on antimicrobial utilization and patient outcomeCrit Care Med20134192099210723873275
   PubMed Web of Science ®Google Scholar
• JainRKralovicSMEvansMEVeterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infectionsN Engl J Med2011364151419143021488764
   PubMed Web of Science ®Google Scholar
• HuskinsWCHuckabeeCMO’GradyNPSTAR*ICU Trial InvestigatorsIntervention to reduce transmission of resistant bacteria in intensive careN Engl J Med2011364151407141821488763
   PubMed Web of Science ®Google Scholar
• HuangAMNewtonDKunapuliAImpact of rapid organism identification via matrix-assisted laser desorption/ionization time-of-flight combined with antimicrobial stewardship team intervention in adult patients with bacteremia and candidemiaClin Infect Dis20135791237124523899684
   PubMed Web of Science ®Google Scholar